Accueil Ernstrade Bourse Actualite Stock

Place de cotation: Francfort | Londres | Paris | Zurich | Virt-x | Virt-x
Indice: SMI - STOXX 50 - STOXX 600 

La vocation de Roche est de mettre à la disposition du corps médical et des patients des solutions innovantes pour tous et pour chacun. Roche intervient à  tous les niveaux de prise en charge de la maladie pour en diminuer la morbidité et les coûts. L'objectif final est de répondre aux besoins de santé et de garantir la qualité de vie des patients.

Basel, 01 February 2017
Roche reports good results in 2016
Group sales increase 4%1 at constant exchange rates, 5% in Swiss francs
Pharmaceuticals Division sales up 3%, mainly driven by cancer medicines Perjeta and Herceptin as well as Actemra/RoActemra
Diagnostics Division sales grow 7%, driven primarily by immunodiagnostic solutions
Successful launches of four new medicines; five US FDA breakthrough therapy designations granted
Emicizumab prophylaxis shows positive results in people with haemophilia A in pivotal trial
Successful launch of new immunochemistry instrument cobas e 801
Core earnings per share up 5% at constant exchange rates, 8% in Swiss francs
Board proposes dividend increase to CHF 8.20
Outlook for 2017: sales expected to grow low- to mid-single digit, at constant exchange rates. Core earnings per share targeted to grow broadly in line with sales, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.
Key figures 2016
CHF millions        % change   
2016    2015    CER1    CHF
Group sales    50,576    48,145    +4    +5
Pharmaceuticals Division    39,103    37,331    +3    +5
Diagnostics Division    11,473    10,814    +7    +6
Core operating profit    18,420    17,542    +4    +5
Core EPS - diluted (CHF)    14.53    13.49    +5    +8
IFRS net income    9,733    9,056    +7    +7
Commenting on the Group’s results, Roche CEO Severin Schwan said: «I am pleased that we have again reached all our financial targets while our product portfolio has made significant progress. We brought four new medicines to market in less than a year, including our first cancer immunotherapy Tecentriq. In Diagnostics, we launched an immunodiagnostic instrument, the cobas e 801, which represents a major step forward in realising the connected laboratory. We again look forward to a number of important clinical read-outs and regulatory milestones for Roche medicines this year, reflecting our broad and innovative product pipeline.»
Group results
Good performance in both divisions
Group sales rose 4% to CHF 50.6 billion. Despite high investments in the launch of new products and product development, core EPS grew faster than sales (+5%). Core EPS growth reflects the good underlying business performance and an impact from changes to the Group's Swiss pension plans. IFRS net income was up 7% at constant exchange rates and in Swiss francs.
Sales in the Pharmaceuticals Division rose 3% to CHF 39.1 billion, driven by growth of Perjeta, Herceptin and Actemra/RoActemra, partially offset by lower sales of Pegasys, Tarceva and Lucentis.
In the US, Pharmaceuticals sales advanced 3%, led by the respiratory medicines Xolair and Esbriet. The recently launched medicines Tecentriq and Alecensa contributed to the growth as well. Sales of eye drug Lucentis and cancer medicines Avastin and Tarceva declined due to growing use of other therapeutic options. In Europe, sales growth of 4% was driven by Perjeta, Actemra/RoActemra and MabThera/Rituxan. In Japan, sales grew 1% despite the biennial price cuts and a special price reduction rule for best-selling medicines. Tamiflu, Alecensa and Actemra/RoActemra were key sales contributors. In the International region, sales gained 4%, driven by the Asia-Pacific and Latin America subregions.
Diagnostics divisional sales increased 7% to CHF 11.5 billion – above market growth. Centralised and Point of Care Solutions2 was the main contributor, led by its immunodiagnostics business.
In the EMEA3 (+2%) and North America (+3%) regions, the division’s largest markets, the sales increases were led by Centralised and Point of Care Solutions. Sales growth in North America was partially offset by a decline in Diabetes Care business, which faced continued pricing pressure. The sales increase in Asia-Pacific (+16%) was mainly driven by China. In Latin America, sales advanced 18%. Sales growth in Japan (+2%) was also led by the Centralised and Point of Care Solutions business.


Copyright 2017